Oncogenomics to Identify and Validate Novel Targeted Therapies in Multiple Myelom

肿瘤基因组学识别和验证多发性骨髓瘤的新型靶向疗法

• 批准号: 8566798
• 负责人: KENNETH C. ANDERSON
• 金额: $ 21.48万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-01 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8566798
• 关键词: Apoptosis; Biological Assay; Biological Models; Bone Marrow; Bortezomib; Cell Line; Cell Survival; Cells; Clinic; Clinical; Clinical Research; Clinical Trials; Combined Modality Therapy; Data; Databases; Development; Disease Progression; Disease remission; Drug resistance; Frequencies; Future; Genes; Human; In Vitro; Instruction; Laboratory Finding; Mediating; Molecular; Molecular Target; Multiple Myeloma; Mutation; Newly Diagnosed; Outcome; Pathway interactions; Patients; Phase; Pre-Clinical Model; Relapse; Role; Therapeutic; Therapeutic Agents; Translating; Treatment Efficacy; Tumor Suppressor Genes; Validation; aurora-A kinase; base; cancer genomics; caspase-8; caspase-9; cell growth; clinically relevant; clinically significant; cytotoxicity; design; high throughput screening; improved; in vivo; in vivo Model; lenalidomide; loss of function; neoplastic cell; new therapeutic target; next generation; novel; partial response; pre-clinical; prognostic; response; small hairpin RNA; translational study; treatment strategy; tumor

PROJECT SUMMARY (See instructions): We have utilized our in vitro and in vivo models of the multiple myeloma (MM) cell in the BM milieu to demonstrate the molecular mechanisms whereby novel agents target tumor cells, host interactions, and the BM microenvironment to overcome conventional drug resistance. We have then rapidly translated these laboratory findings to the clinic leading to FDA approvals of six novel treatments in the past five years; importantly, the median survival of MM patients has been extended from 3 to 7 years as a direct result of these advances. Our preclinical in vitro and in vivo efforts combining bortezomib with lenalidomide demonstrated synergistic MM cytotoxicity, and our derived clinical trials in newly diagnosed patients showed remarkable response; together, these data provided the rationale for the proposed clinical study in Project 1. We hypothesize that genetic changes identified using extensive oncogenomic profiling in Projects 2 and 4 represent novel therapeutic targets in MM. In this Project, we will use our robust human MM model systems to stringently validate the role of these novel targets in MM cell growth, survival, and drug resistance; and assess the therapeutic potential of these targets, both alone and in combination with established and emerging MM therapeutics. We will use a high-throughput shRNA-based assay directed at these targets to identify those regulating MM cell growth and survival in vitro (Specific Aim 1); validate the functional role of selected molecular targets regulating MM cell growth, survival, and drug resistance using our in vitro and in vivo models of human MM in the bone marrow milieu (Specific Aim 2); and evaluate the impact of potential therapeutic agents directed against these validated novel molecular targets, alone and in combination in MM (Specific Aim 3). This proposal will therefore identify the next generation of targeted therapies in MM.

项目总结（见说明书）：我们利用骨髓环境中多发性骨髓瘤（MM）细胞的体外和体内模型来证明新型药物靶向肿瘤细胞、宿主相互作用和骨髓微环境克服传统耐药性的分子机制。然后，我们迅速将这些实验室发现转化为临床，导致FDA在过去五年中批准了六种新型治疗方法;重要的是，MM患者的中位生存期从3年延长到7年，这是这些进展的直接结果。我们的临床前体外和体内研究证明硼替佐米与来那度胺联合使用具有协同MM细胞毒性，我们在新诊断患者中的衍生临床试验显示出显著的缓解;总之，这些数据为项目1中拟定的临床研究提供了依据。我们假设在项目2和4中使用广泛的癌基因组分析鉴定的遗传变化代表MM中的新治疗靶点。在该项目中，我们将使用我们强大的人类MM模型系统来严格验证这些新靶点在MM细胞生长、存活和耐药性中的作用;并评估这些靶点的治疗潜力，无论是单独使用还是与已建立的和新出现的MM治疗药物联合使用。我们将使用针对这些靶点的基于shRNA的高通量测定来鉴定那些在体外调节MM细胞生长和存活的靶点。（具体目标1）;使用我们的体外和体内人MM模型，在骨髓环境中验证所选分子靶标调节MM细胞生长、存活和耐药性的功能作用。（具体目标2）;并评价针对这些经验证的新型分子靶点的潜在治疗药物单独和联合治疗MM的影响（具体目标3）。因此，该提案将确定MM的下一代靶向治疗。